Clinical Trial Update: A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the safety and effectiveness of GAMMAPLEX in chronic immune thrombocytopenic purpura has completed, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenic Purpura

Drugs mentioned

• GAMMAPLEX (intravenous immunoglobulin (IVIG))

Snippet

Sponsor: Bio Products Laboratory | Conditions: Chronic Idiopathic Thrombocytopenic Purpura | Phase 3 | Status: COMPLETED | Results posted: 2012-06-06